Extended Thromboprophylaxis with Low Molecular Weight Heparin Reduces Symptomatic Venous Thromboembolism following Lower Limb Arthroplasty - a Meta-analysis

A. T. Cohen; C. S. Bailey; R. Alikhan; D. J. Cooper

doi:10.1055/s-0037-1615775

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2001; 85(05): 940-941
DOI: 10.1055/s-0037-1615775

Letters to the Editor

Schattauer GmbH

Extended Thromboprophylaxis with Low Molecular Weight Heparin Reduces Symptomatic Venous Thromboembolism following Lower Limb Arthroplasty - a Meta-analysis

A. T. Cohen

¹Academic Department of Surgery

,

C. S. Bailey

¹Academic Department of Surgery

,

R. Alikhan

¹Academic Department of Surgery

,

D. J. Cooper

²Computing Services, Guy‘s, King‘s and St. Thomas‘s School of Medicine and Dentistry, London, UK

References
1 Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996; 348: 224-8.
2 Bergqvist D, Benoni G, Bjorgell O, Fredin H, Hedlundh U, Nicolas S, Nelsson P, Nylander G. Low-molecular-weight heparin (enoxaparin) as prophylaxis against thromboembolism after total hip replacement. N Engl J Med 1996; 335: 696-700.
3 Dahl OE, Andreassen G, Aspelin T, Muller C, Mathiesen P, Nyhus S, Abdelnoor M, Solhaug JH, Arnesen H. Prolonged thromboprophylaxis following hip replacement surgery - results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin®). Thromb Haemost 1997; 77: 26-31.
4 Lassen MR, Borris LC, Anderson BS, Jensen HP, Skejo Bro HP, Anderson G, Peterson AO, Siem P, Horlyck E, Jensen BV, Thomsen PB, Hansen BR, Erin-Madsen J, Moller JC, Rotwitt L, Christensen F, Nielsen JB, Jorgensen PS, Paaske B, Torholm C, Hvidt P, Jensen NK, Nielsen AB, Appelquist E, Tjalve E. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty - the Danish Prolonged Prophylaxis (DaPP) Study. Thromb Res 1998; 89: 281-7.
5 Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K, Holmqvist A, Mant M, Dear R, Baylis B, Mah A, Brant R. Low-molecular weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med. 2000; 160 (Suppl. 14) 2208-15.
6 Heit JA, Elliott CG, Trowbridge AA, Morrey BF, Gent M, Hirsh J. for the Ardeparin Arthroplasty Study Group. Ardeparin Sodium for extended out-of-hospit l prophyl xis g inst venous thromboembolism fter tot l hip or knee replacement. A randomised, double-blind, placebo-controlled trial. Ann Intern Med. 2000; 132: 853-61.